heksa4
whether of new innovative treatments or medicines of limited availability with new generic options.

Population aging and a growing number of new therapeutic options represent a challenge for the management of healthcare budget and the value-based decision making for payors. Whether we are preparing reimbursement proposals for new innovative treatments, or for medicines of limited availability with new generic options, we at Makpharm always strive to maximize medicine availability to patients, offering at the same time affordable terms for payors.